Related Experiment Video
Updated: Mar 1, 2026

Targeted Next-generation Sequencing and Bioinformatics Pipeline to Evaluate Genetic Determinants of Constitutional Disease
Published on: April 4, 2018
Genome annotation for clinical genomic diagnostics: strengths and weaknesses
Charles A Steward1,2, Alasdair P J Parker3, Berge A Minassian4,5
1Congenica Ltd, Wellcome Genome Campus, Hinxton, Cambridge, CB10 1DR, UK. charles.steward@congenica.com.
Abstract:
The Human Genome Project and advances in DNA sequencing technologies have revolutionized the identification of genetic disorders through the use of clinical exome sequencing. However, in a considerable number of patients, the genetic basis remains unclear. As clinicians begin to consider whole-genome sequencing, an understanding of the processes and tools involved and the factors to consider in the annotation of the structure and function of genomic elements that might influence variant identification is crucial. Here, we discuss and illustrate the strengths and weaknesses of approaches for the annotation and classification of important elements of protein-coding genes, other genomic elements such as pseudogenes and the non-coding genome, comparative-genomic approaches for inferring gene function, and new technologies for aiding genome annotation, as a practical guide for clinicians when considering pathogenic sequence variation. Complete and accurate annotation of structure and function of genome features has the potential to reduce both false-negative (from missing annotation) and false-positive (from incorrect annotation) errors in causal variant identification in exome and genome sequences. Re-analysis of unsolved cases will be necessary as newer technology improves genome annotation, potentially improving the rate of diagnosis.
More Related Videos
Related Concept Videos
Genomics
Genome-wide Association Studies-GWAS
GWAS does not require the identification of the target gene involved in...
Genome Annotation and Assembly
Modern Molecular Taxonomy
Pharmacogenomics: Identification of New Drug Targets

